Introduction GeoMx® Digital Spatial Profiler (DSP) is one of the leading revolutionary technologies that elevate spatial biology to new heights and is a core force in driving the forefront of spatial multi-omics research and clinical translation practices. It meets the research and application needs at different stages across various fields such as oncology, tumor immunology, … Read more
Due to the involvement of NTRK gene fusions in various tumors, their occurrence is rare, and the standard therapies (SoC) and prognoses for different tumors vary. Conducting clinical trials of TRK inhibitors using the “gold standard” randomized controlled trials (RCTs) is often impractical. Currently, clinical trials for TRK inhibitors mostly employ single-arm basket study designs … Read more
“The Late Spring Festival”! In 2020, as the Mid-Autumn Festival coincided with National Day, each person’s feelings and reflections on the tumultuous past six months and the sense of loss and recovery are countless. As families reunite, let us together remember the past and cherish the present! The National Day holiday is already halfway through. … Read more
The 4th Global Biopharmaceutical Frontier Technology Conference and Exhibition is Open for Registration! The story of the “magic bullet” ADC has clearly not reached its final chapter. With the advent of DS-8201, the global ADC market has become exceptionally vibrant, entering a period of rapid growth. The market’s enthusiasm for ADCs is evident from the … Read more
Expert Commentary Professor Feng Jifeng Chief Physician, Professor, Doctoral Supervisor Secretary of the Party Committee, Jiangsu Provincial Cancer Hospital/Nanjing Medical University Affiliated Cancer Hospital Member of the Expert Committee on Rational Drug Use, National Health Commission Council Member of the Chinese Medical Association, Member of the Internal Medicine Group of the Oncology Branch Vice President … Read more
Currently, 15 ADC drugs have been approved globally, of which 6 are approved in China, namely Enfortumab vedotin, Brentuximab vedotin, Trastuzumab deruxtecan, Gemtuzumab ozogamicin, Sacituzumab govitecan, and Loncastuximab tesirine. This article provides a brief summary of the currently approved ADC drugs, the types of tumors they are suitable for, and how to use them. 1. … Read more